Lantern Pharma announced key advances in applying its RADR® AI platform to streamline and de-risk antibody-drug conjugate (ADC) programs. The ADC market is projected to hit $30.4B by 2028 (41.7% CAGR), driven by new blockbuster ADCs surpassing $1B in annual sales and over $10B in recent pharma acquisitions targeting the space.
